Start › Niedrobnokomórkowy rak płuca › Ohio › Cleveland
Badania kliniczne dla Niedrobnokomórkowy rak płuca w mieście Cleveland, OH
43 badań dla Niedrobnokomórkowy rak płuca szuka uczestników w ośrodkach w mieście Cleveland i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekrutacjaFaza 3
- MetroHealth Medical Center, Cleveland
- Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
- Cleveland Clinic Foundation, Cleveland
- i 2 więcej
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekrutacjaFaza 1
- University Hospitals Cleveland Medical Center, Cleveland
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekrutacjaFaza 1/2
- The Cleveland Clinic Taussig Cancer Center, Cleveland
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
RekrutacjaFaza 1/2
- Research Site, Cleveland
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekrutacjaFaza 1
- Exelixis Clinical Site #10, Cleveland
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
RekrutacjaFaza 3
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic, Cleveland
- Cleveland Clinic - Hillcrest Hospital, Mayfield Heights · 12 mi dalej
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RekrutacjaFaza 3
- University Hospitals Cleveland Medical Center, Cleveland
- UH Minoff Health Center at Chagrin Highlands, Orange · 12 mi dalej
- University Hospitals Seidman Cancer Center at UH Mentor Health Center, Mentor · 22 mi dalej
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekrutacjaFaza 3
- University Hospitals Cleveland Medical Center, Cleveland
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
RekrutacjaFaza 2
- University Hospitals Cleveland Medical Center, Cleveland
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RekrutacjaFaza 3
- University Hospitals Cleveland Medical Center, Cleveland
- UH Minoff Health Center at Chagrin Highlands, Orange · 12 mi dalej
- University Hospitals Seidman Cancer Center at UH Mentor Health Center, Mentor · 22 mi dalej
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RekrutacjaFaza 3
- Fairview Hospital, Cleveland
- Cleveland Clinic, Cleveland
- Cleveland Clinic - Hillcrest Hospital, Mayfield Heights · 12 mi dalej
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RekrutacjaFaza 1/2
- Cleveland Clinic, Cleveland
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
RekrutacjaFaza 2
- Research Site, Cleveland
Pulmonary Rehabilitation in Advanced Lung Cancer Survivors
RekrutacjaFaza 2
- University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
RekrutacjaFaza 2/3
- The Cleveland Clinic Cancer Center At Fairview Hospital, Moll Pavilion, Cleveland
- Cleveland Clinic, Cleveland
- Cleveland Clinic - Hillcrest Hospital, Mayfield Heights · 12 mi dalej
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RekrutacjaFaza 2/3
- University Hospitals Cleveland Medical Center, Cleveland
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RekrutacjaFaza 3
- Clinical Study Site, Cleveland
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
RekrutacjaFaza 1/2
- Cleveland Clinic, Cleveland
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RekrutacjaFaza 2/3
- University Hospitals Cleveland Medical Center, Cleveland
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RekrutacjaBadanie obserwacyjne
- Cleveland Clinic, Cleveland
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RekrutacjaFaza 1
- University Hospital Cleveland Medical Center, Cleveland
- Cleveland Clinic, Cleveland
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
RekrutacjaFaza 1/2
- Case Western Reserve University, Cleveland
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
RekrutacjaFaza 1
- Cleveland Clinic, Cleveland
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
RekrutacjaFaza 1
- Cleveland Clinic, Cleveland
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
RekrutacjaFaza 1/2
- Cleveland Clinic Taussig Cancer Center, Cleveland
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
RekrutacjaFaza 1/2
- Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center, Cleveland
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
RekrutacjaFaza 1
- Cleveland Clinic, Cleveland
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RekrutacjaFaza 1
- Cleveland Clinic Taussig Cancer Institute, Cleveland
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
RekrutacjaFaza 1/2
- Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center, Cleveland
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
RekrutacjaFaza 1
- University Hospital - Cleveland Medical Center, Cleveland
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
RekrutacjaFaza 3
- University Hospitals Cleveland Medical Center, Cleveland
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RekrutacjaFaza 1
- University Hospitals Cleveland Medical Center, Cleveland
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
RekrutacjaFaza 1/2
- University Hospitals Cleveland, Cleveland
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
RekrutacjaFaza 1/2
- University Hospitals Cleveland Medical Center, Cleveland
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
RekrutacjaFaza 1
- Research Site, Cleveland
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
RekrutacjaFaza 1
- University Hospitals - UH Cleveland Medical Center, Cleveland
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
RekrutacjaFaza 2
- Cleveland Clinic, Cleveland
A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
RekrutacjaFaza 1/2
- Gabrail Cancer Center, Ohio City · 1 mi dalej
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Rekrutacja
- Louis Stokes VA Medical Center, Cleveland, OH, Cleveland
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
RekrutacjaFaza 1/2
- Cleveland Clinic, Cleveland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekrutacjaBadanie obserwacyjne
- Massive Bio SYNERGY-AI site, Mayfield Heights · 12 mi dalej
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
RekrutacjaFaza 1/2
- Cleveland Clinic, Cleveland
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
RekrutacjaFaza 2
- Cleveland Clinic, Cleveland
Badania dla Niedrobnokomórkowy rak płuca w innych miastach
- Houston, TX145 badań
- New York City, NY121 badań
- Arlington, VA104 badań
- Nashville, TN97 badań
- Boston, MA90 badań
- Los Angeles, CA87 badań
- St. Louis, MO73 badań
- Chicago, IL61 badań
- Baltimore, MD60 badań
- San Antonio, TX59 badań
- Columbus, OH57 badań
- Washington, DC55 badań
Inne badania w mieście Cleveland
- Nowotwory (wszystkie typy)36 badań
- Rak piersi35 badań
- Rak prostaty34 badań
- Niewydolność serca33 badań
- Rak jajnika30 badań
- Nowotwór przerzutowy30 badań
- Rak płuc26 badań
- Rak jelita grubego i odbytnicy24 badań
- Choroby układu sercowo-naczyniowego22 badań
- Rak endometrium20 badań
- Ostra białaczka szpikowa20 badań
- Choroba Leśniowskiego-Crohna19 badań
Źródło: ClinicalTrials.gov, dane pobrane 6 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.